17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts

Clinical Cancer Research

Volumn 8, Issue 5, 2002, Pages 986-993

  Solit, David B ^a   Zheng, Fuzhong F ^a   Drobnjak, Maria ^a   Münster, Pamela N ^a   Higgins, Brian ^a   Verbel, David ^a   Heller, Glenn ^a   Tong, William ^a   Cordon Cardo, Carlos ^a   Agus, David B ^a   Scher, Howard I ^a   Rosen, Neal ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANDROGEN RECEPTOR; ANSAMYCIN DERIVATIVE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CASTRATION; ENZYME INDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIGAND BINDING; ONCOGENE NEU; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; TARGET CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANDROGENS; ANIMALS; BENZOQUINONES; CELL DIVISION; DOWN-REGULATION; FEMALE; G1 PHASE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, ANDROGEN; RETINOBLASTOMA PROTEIN; RIFABUTIN; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036091221     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Endocrine treatment of prostate cancer - Recent developments and the future. Part 1: Maximal androgen blockade, early vs. delayed endocrine treatment and side-effects
2. Androgen receptors in endocrine-therapy-resistant human prostate cancer
3. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
4. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist
5. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
6. Androgen receptor activation in prostate tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
7. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
8. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway
9. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
10. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation
11. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent
12. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone
13. In vivo functions of the Saccharomyces cerevisiae Hsp90 chaperone
14. Hsp90's secrets unfold: New insights from structural and functional studies
15. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signaling pathway
16. Hsp90 regulates androgen receptor hormone binding affinity in vivo
17. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association
18. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
19. Polypeptide release by hsp90 involves ATP hydrolysis and is enhanced by the co-chaperone p23
20. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin
21. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells
22. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin
23. Assessment of neuronal viability with Alamar blue and granule cell cultures
24. Flow cytometric analysis of G1- and G2/M-phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements
25. Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence
26. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models
27. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations
28. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest
29. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells
30. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone
31. Ligand responsiveness in human prostate cancer: Structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors
32. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway
33. Androgen receptor gene mutations in hormone-refractory prostate cancer
34. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer
35. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor
36. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization
37. Her-2-neu expression and progression toward androgen independence in human prostate cancer
38. Modulation of Akt kinase activity by binding to Hsp90